Takeda Pharmaceutical Co Azioni (NYSE: TAK)

Takeda Pharmaceutical Co (NYSE:TAK) Azioni

Takeda Pharmaceutical Co

Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Pfizer_shutterstock2

Biotech

Large Cap

News

Health Care

General

L&#39;approvazione di un nuovo farmaco offre nuove speranze per i pazienti con linfoma avanzato. Come cambia l&#39;approccio terapeutico?

Adcetris di Pfizer: una speranza per i pazienti con linfoma di Hodgkin

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co Ltd

TransAKT Ltd

TAKIGAMI STEEL CONSTRCTN by Takigami Steel Construction Co. Ltd.

Takigami Steel Construction Co Ltd

TAKAMATSU CONSTRUCTION GR by TAKAMATSU CONSTRUCTION GROUP CO LTD

Takamatsu Construction Group Co Ltd

VOLATUS AEROSPACE INC by VOLATUS AEROSPACE INC.

Volatus Aerospace Inc

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) raises FY2025 sales outlook from $254.00 million-$265.00 million to $256.00 million-$265.00 million vs $260.00 million estimate.

Guidance

Viemed Healthcare Raises FY2025 Sales Guidance from $254.00M-$265.00M to $256.00M-$265.00M vs $260.00M Est

Global Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNL#NYSE">GNL</a>) affirms FY2025 FFO guidance from $0.90-$0.96 to $0.90-$0.96 vs $1.00 analyst estimate..

Global Net Lease Affirms FY2025 FFO Guidance of $0.90-$0.96 vs $1.00 Est

Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) affirms FY2025 Adj EPS guidance from $0.41-$0.51 to $0.41-$0.51 vs $0.38 analyst estimate. Affirms FY2025 sales outlook from $1.05 billion-$1.08 billion to $1.05 billion-$1.08 billion vs $1.07 billion estimate.

EHAB

Enhabit Affirms FY2025 Adj EPS Guidance of $0.41-$0.51 vs $0.38 Est; Affirms FY2025 Sales Guidance of $1.05B-$1.08B vs $1.07B Est

Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.14 by 228.57 percent. This is a 611.11 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $78.00 million which beat the analyst consensus estimate of $75.41 million by 3.44 percent. This is a 15.00 percent increase over sales of $67.83 million the same period last year.

Earnings

Earnings Beats

CRNC

Cerence Q2 EPS $0.46 Beats $0.14 Estimate, Sales $78.00M Beat $75.41M Estimate

Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) shares are rising in after-hours Wednesday after the company beat first-quarter estimates and raised its <a href="https://www.benzinga.com/pressreleases/25/05/n45265409/axon-reports-q1-2025-revenue-of-604-million-up-31-year-over-year">full-year guidance</a>.
Q1 Earnings: Axon reported first-quarter revenue of $603.63 million, beating analyst estimates of $583.76 million. The company reported first-quarter adjusted earnings of $1.41 per share, beating analyst estimates of $1.27 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 31% year-over-year. Axon&#8217;s first-quarter results were led by strength in Software and Services, which generated&nbsp;$263 million&nbsp;in revenue, up&nbsp;39%&nbsp;year-over-year.
Axon raised its full-year guidance from a range of $2.55 billion to $2.65 billion to a new range of $2.6 billion to $2.7 billion versus estimates of $2.62 billion.
&#8220;Strong alignment with our customers, expanding vertical applications and sustained product innovation underpin Axon&#8217;s increased&nbsp;outlook&nbsp;for the remainder of the year,&#8221; the company said.
AXON Price Action: <a href="http://benzinga.com/quote/axon">Axon Enterprise shares</a> were up 4.68% at $630 in extended trading at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45269045/applovin-stock-shakes-off-short-seller-report-shares-surge-on-q1-earnings-beat">AppLovin Stock Shakes Off Short Seller Report, Shares Surge On Q1 Earnings Beat</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

After-Hours Center

Movers

AXON

Axon Enterprise Stock Pops On Q1 Earnings: Key Details

Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) affirms FY2025 sales outlook from $235.00 million-$255.00 million to $235.00 million-$255.00 million vs $267.50 million estimate.

ISPO

Inspirato Affirms FY2025 Sales Guidance of $235.00M-$255.00M vs $267.50M Est

Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) sees FY2026 sales of $15.208 billion vs $15.14 billion analyst estimate.

Kyndryl Hldgs Sees FY2026 Revenue to be up by 1% YoY

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 15 years by 5.78% on an annualized basis producing an average annual return of 16.87%. Currently, RBC Bearings has a market capitalization of $10.76 billion. 
Buying $1000 In RBC: If an investor had bought $1000 of RBC stock 15 years ago, it would be worth $10,291.73 today based on a price of $342.20 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746656111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In RBC Bearings 15 Years Ago Would Be Worth This Much Today

Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) reported quarterly earnings of $0.41 per share. This is a 2.5 percent increase over earnings of $0.40 per share from the same period last year. The company reported $65.45 million in sales this quarter. This is a 14.74 percent increase over sales of $57.04 million the same period last year.

Smartstop Self Storage Q1 FFO $0.41 Up From $0.40 YoY, Sales $65.45M Up From $57.04M YoY

goeasy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GSY#TSX">GSY</a>) affirms FY2025 sales outlook from $1.62 billion-$1.82 billion to $1.62 billion-$1.82 billion.

TSX:GSY

goeasy Affirms FY2025 Sales Guidance of $1.62B-$1.82B

WIIM

BROS

BROS stock has given up its prior gain. Dutch Bros shares were trading higher after the company reported better-than-expected Q1 financial results.

B2Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>) reported quarterly earnings of $0.09 per share which met the analyst consensus estimate. This is a 50 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $532.11 million which missed the analyst consensus estimate of $579.94 million by 8.25 percent. This is a 15.31 percent increase over sales of $461.44 million the same period last year.

Earnings Misses

B2Gold Q1 Adj. EPS $0.09, Inline, Sales $532.11M Miss $579.94M Estimate

MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) shares are rising in extended trading on Wednesday after the company reported better-than-expected results <a href="https://www.benzinga.com/pressreleases/25/05/g45267551/mercado-libre-builds-on-2024-momentum-with-strong-q1-2025-results-reporting-5-9-billion-revenue-an">for the first quarter</a>.
<ul>
<li>Q1 Revenue: $5.93 billion, versus <a href="http://benzinga.com/quote/meli/estimates">estimates</a> of $5.51 billion</li>
</ul>
<ul>
<li>Q1 EPS: $9.74, versus estimates of $8.03</li>
</ul>
Total revenue increased 37% on a year-over-year basis, boosted by continued strategic investments. Commerce revenue climbed 32% year-over-year, Financial revenue increased 37% and Fintech revenue from Mercado Pago jumped 43%. 
The Latin America e-commerce and fintech platform company said brand preference reached all-time highs in key markets during the quarter, including Brazil, Mexico, Argentina and Chile. 
&#8220;Mercado Libre started 2025 with exceptional momentum, driven by strong operational performance across both commerce and fintech,&#8221; said Martin de los Santos, CFO of MercadoLibre.
&#8220;This quarter highlights our continued commitment to sustainable, profitable growth as we capture the many opportunities ahead. We remain a key force in accelerating the shift from traditional retail to e-commerce, supported by ongoing investments aimed at delivering a seamless user experience.&#8221;
MELI Price Action: <a href="http://benzinga.com/quote/meli">MercadoLibre shares</a> were up 1.48% in Wednesday&#8217;s after-hours session, trading at $2,262.09 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45183831/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-63">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Octavio_Hoyos">Octavio Hoyos</a>/Shutterstock.

Fintech news covering the emerging Financial Technology services sector

Fintech

Global

MELI

MercadoLibre Stock Surges On Q1 Earnings Beat: 'Exceptional Momentum'

Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDO#NYSE">BBDO</a>) reported quarterly earnings of $0.09 per share. This is a 21.43 percent increase over earnings of $0.07 per share from the same period last year. The company reported $3.82 billion in sales this quarter. This is a 4.63 percent increase over sales of $3.65 billion the same period last year.

BBDO

Bank Bradesco Q1 EPS $0.09 Up From $0.07 YoY, Sales $3.82B Up From $3.65B YoY

Pizza Pizza Royalty (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PZA#TSX">PZA</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported $9.73 million in sales this quarter. This is a 1.85 percent increase over sales of $9.55 million the same period last year.

TSX:PZA

Pizza Pizza Royalty Q1 Adj. EPS $0.23, Inline, Sales $9.73M Up From $9.55M YoY

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.54, a high estimate of $4.50, and a low estimate of $1.00. This current average represents a 28.85% decrease from the previous average price target of $3.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655276_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Offerpad Solutions by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$1.00</td>
<td>$2.25</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$2.25</td>
<td>$3.15</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Offerpad Solutions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Offerpad Solutions compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Offerpad Solutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Offerpad Solutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Offerpad Solutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Offerpad Solutions</h2>
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
<h3>Offerpad Solutions: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Offerpad Solutions's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -27.52% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.94%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Offerpad Solutions's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.84%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Offerpad Solutions's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Offerpad Solutions's debt-to-equity ratio stands notably higher than the industry average, reaching 5.0. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OPAD

What Analysts Are Saying About Offerpad Solutions Stock

Across the recent three months, 7 analysts have shared their insights on Expeditors International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $113.29, a high estimate of $128.00, and a low estimate of $105.00. Highlighting a 3.85% decrease, the current average has fallen from the previous average price target of $117.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655268_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Expeditors International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$108.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Expeditors International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Expeditors International compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Expeditors International's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXPD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Expeditors International analyst ratings.</a>
<h2>All You Need to Know About Expeditors International</h2>
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
<h3>A Deep Dive into Expeditors International's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Expeditors International's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.72%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Expeditors International's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.98% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Expeditors International's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Expeditors International's debt-to-equity ratio is below the industry average. With a ratio of 0.26, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPD

What 7 Analyst Ratings Have To Say About Expeditors International

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) sees Q2 sales of $235.000 million-$243.000 million vs $243.71 million analyst estimate.

BMBL

Bumble Sees Q2 Sales $235.000M-$243.000M vs $243.71M Est

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.36, a high estimate of $29.00, and a low estimate of $7.00. A decline of 17.71% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655260_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Myriad Genetics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Myriad Genetics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Key Indicators: Myriad Genetics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.12% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MYGN

What Analysts Are Saying About Myriad Genetics Stock

In the preceding three months, 5 analysts have released ratings for Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $36.0, a high estimate of $45.00, and a low estimate of $27.00. Highlighting a 5.76% decrease, the current average has fallen from the previous average price target of $38.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655250_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viridian Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Viridian Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Viridian Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRDN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Viridian Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Viridian Therapeutics</h2>
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
<h3>Unraveling the Financial Story of Viridian Therapeutics</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Viridian Therapeutics's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately 0.0% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -110729.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -15.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.53%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRDN

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

Press Releases

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Comments

Takeda Pharmaceutical Co

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO